Leap Therapeutics

04/11/2024

We’re excited to announce a $40 million equity financing. Thank you to our strategic and institutional investors for supporting our mission to develop DKN-01 to treat GI cancer patients around the world.

Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development program CAMBRIDGE, Mass. , April 11, 2024 /PRNewswire/ -- Leap Therapeutics, Inc.

07/13/2023

For more background on DKN-01 and our DeFianCe study in patients, read this interview with Dr. John Strickler of Duke University from earlier this year. Making a difference for CRC patients is our mission at Leap.

In an interview with Targeted Oncology, John Strickler, MD, discussed the background and goals of the DeFianCe study in the colorectal cancer space.

07/12/2023

DKN-01 is moving into a second randomized controlled trial! This time in patients. Early efficacy data and high investigator/patient enthusiasm mark another milestone for DKN-01. Thank you to everyone involved in the DeFianCe study.

CAMBRIDGE, Mass. , July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on the early efficacy and momentum seen in the enrollment of 33 patients with colorectal

06/05/2023

Today at , updated data from Part A of the DisTinGuish Study of DKN-01 + BeiGene's tislelizumab + chemo in was presented as a poster and in a discussion session. https://www.leaptx.com/wp-content/uploads/2023/06/ASCO-2023-226390_A2838_poster_ppt.pdf?_gl=1*spmwai*_up*MQ..*_ga*NTI2OTQxNTU4LjE2ODU5ODk3NTQ.*_ga_SBRE9X09Y0*MTY4NTk4OTc1NC4xLjEuMTY4NTk4OTc1Ny4wLjAuMA..

05/26/2023

Join us at as we present updated data from Part A of the DisTinGuish Study! Dr. Sam Klempner will be sharing insights on DKN-01 + BeiGene's tislelizumab & chemo in patients at the poster and discussion session on Monday, June 5th, 11:30 AM CT.

19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overall mITT population, including 86% ORR in PD-L1-low patients CAMBRIDGE, Mass.